Volume 121, Issue 5, Pages (November 2001)

Slides:

Advertisements

Similar presentations

Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado

Advertisements

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 117, Issue 2, Pages (August 1999)

Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial K. Balighi, S.Z.

AGA technical review on irritable bowel syndrome

Volume 126, Issue 1, Pages (January 2004)

Volume 123, Issue 4, Pages (October 2002)

Volume 125, Issue 3, Pages (September 2003)

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert.

Abatacept for Crohn's Disease and Ulcerative Colitis

Volume 122, Issue 3, Pages (March 2002)

Volume 135, Issue 4, Pages (October 2008)

Volume 119, Issue 2, Pages (August 2000)

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? William E. Whitehead, Olafur.

Polyxeni Koutkia, Zhiren Lu, Tai C. Chen, Michael F. Holick

Volume 133, Issue 1, Pages (July 2007)

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Stephen B Hanauer, Carrie L Wagner,

A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of.

Appendectomy is followed by increased risk of Crohn's disease

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg

Volume 115, Issue 1, Pages (July 1998)

GI clinical research 2002–2003: the year in review

Yung-Chih Chen, MD, Wan-Ting Chiu, MD, Mai-Szu Wu, MD

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Volume 74, Issue 5, Pages (November 2018)

Volume 130, Issue 2, Pages (February 2006)

Volume 147, Issue 3, Pages e3 (September 2014)

Volume 123, Issue 2, Pages (August 2002)

Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study William J. Sandborn, William F. Stenson,

Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek

Volume 132, Issue 5, Pages (May 2007)

Volume 117, Issue 2, Pages (August 1999)

Volume 119, Issue 6, Pages (December 2000)

Adalimumab Induces Deep Remission in Patients With Crohn's Disease

William J. Sandborn, Stefan Schreiber, Brian G

Volume 119, Issue 6, Pages (December 2000)

Volume 154, Issue 6, Pages (May 2018)

Volume 132, Issue 1, Pages (January 2007)

Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N

David H. Bruining, William J. Sandborn

Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud

AGA technical review on nonalcoholic fatty liver disease

Volume 114, Issue 6, Pages (June 1998)

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease Gerassimos J.

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Volume 126, Issue 2, Pages (February 2004)

Volume 135, Issue 2, Pages (August 2008)

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study William J. Sandborn, Stefan Schreiber,

Volume 121, Issue 5, Pages (November 2001)

Volume 142, Issue 5, Pages e2 (May 2012)

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Volume 126, Issue 1, Pages (January 2004)

AGA technical review on osteoporosis in gastrointestinal diseases

Volume 117, Issue 4, Pages (October 1999)

Volume 117, Issue 3, Pages (September 1999)

Volume 128, Issue 7, Pages (June 2005)

Mesalamine and relapse prevention in Crohn's disease

Emma Janet Castillo, Michael Camilleri, G. Richard Locke, Duane D

Volume 121, Issue 4, Pages (October 2001)

Volume 128, Issue 4, Pages (April 2005)

Volume 134, Issue 3, Pages (March 2008)

Predictors of response to infliximab in patients with Crohn's disease

Medical Therapy for Refractory Pediatric Crohn’s Disease

Volume 121, Issue 2, Pages (August 2001)

Assessing activity of pediatric Crohn's disease: Which index to use?

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months Gary R. Lichtenstein, Ole Ø. Thomsen,

Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Presentation transcript:

Volume 121, Issue 5, Pages 1088-1094 (November 2001) Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial William J. Sandborn, Stephen B. Hanauer, Seymour Katz, Michael Safdi, Douglas G. Wolf, Richard D. Baerg, William J. Tremaine, Therese Johnson, Nancy N. Diehl, Alan R. Zinsmeister Gastroenterology Volume 121, Issue 5, Pages 1088-1094 (November 2001) DOI: 10.1053/gast.2001.28674 Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 1 Percentages of patients with Crohn's disease with clinical response or clinical remission, according to treatment group. None of the differences were statistically significant. (A) Clinical response (decrease in CDAI score from baseline ≥70 points). (B) Clinical remission (CDAI score <150 points). Gastroenterology 2001 121, 1088-1094DOI: (10.1053/gast.2001.28674) Copyright © 2001 American Gastroenterological Association Terms and Conditions

Fig. 2 Median scores at each study visit, according to treatment group. None of the differences were statistically significant. (A) CDAI; (B) IBDQ quality of life index. Gastroenterology 2001 121, 1088-1094DOI: (10.1053/gast.2001.28674) Copyright © 2001 American Gastroenterological Association Terms and Conditions